Evidence map›Paper›PMID 36884108›Full record

ArticlePain and therapy2023

Median Effective Dose of Remifentanil for the Prevention of Pain Caused by the Injection of Rocuronium: An Age-Stratified Study.

Shiting Yan, Hao Wu, Yanlong Yu, Ning Li, Leyang Yu, Ying Wang, Hu Li, Dongsheng Zhang, Zhuan Zhang

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pain and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05217238 (Median Effective Dose of Remifentanil for the Prevention of Pain Caused by the Injection of Rocuronium), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05217238 naunknown statusnot on this map

Median Effective Dose of Remifentanil for the Prevention of Pain Caused by the Injection of Rocuronium

TypeinterventionalSponsorYangzhou UniversityRan2021 to 2022Enrolled70ConditionsRocuronium, Injection PainArmsRemifentanil
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Shiting Yan *Department of Anesthesiology, The Affiliated Hospital of Yangzhou University, Yangzhou University, 368 Hanjiang Middle Road, Yangzhou, 225012, Jiangsu, China.
Hao Wu *Department of Anesthesiology, The Affiliated Hospital of Yangzhou University, Yangzhou University, 368 Hanjiang Middle Road, Yangzhou, 225012, Jiangsu, China.
Yanlong Yu *Department of Anesthesiology, The Affiliated Hospital of Yangzhou University, Yangzhou University, 368 Hanjiang Middle Road, Yangzhou, 225012, Jiangsu, China.
Ning LiDepartment of Anesthesiology, The Affiliated Hospital of Yangzhou University, Yangzhou University, 368 Hanjiang Middle Road, Yangzhou, 225012, Jiangsu, China.
Leyang YuDepartment of Anesthesiology, The Affiliated Hospital of Yangzhou University, Yangzhou University, 368 Hanjiang Middle Road, Yangzhou, 225012, Jiangsu, China.
Ying WangDepartment of Anesthesiology, The Affiliated Hospital of Yangzhou University, Yangzhou University, 368 Hanjiang Middle Road, Yangzhou, 225012, Jiangsu, China.
Hu LiDepartment of Anesthesiology, The Affiliated Hospital of Yangzhou University, Yangzhou University, 368 Hanjiang Middle Road, Yangzhou, 225012, Jiangsu, China.
Dongsheng ZhangDepartment of Anesthesiology, The Affiliated Hospital of Yangzhou University, Yangzhou University, 368 Hanjiang Middle Road, Yangzhou, 225012, Jiangsu, China.
Zhuan ZhangDepartment of Anesthesiology, The Affiliated Hospital of Yangzhou University, Yangzhou University, 368 Hanjiang Middle Road, Yangzhou, 225012, Jiangsu, China. zhangzhuancg@163.com.ORCID http://orcid.org/0000-0002-7295-9013
Northern Jiangsu People's Hospital · CNDalian Medical University · CN

Funding

Beijing Medical Award Foundation Key Project YXJL-2021-0307-0632Social Development Project of Yangzhou Science and Technology Bureau YZ2022108
6 · The paper itself

Abstract

introductionRocuronium intravenous pain is common in induction of general anesthesia. The aim of our study was to determine the median effective dose (ED

methodsEighty-nine adult patients undergoing elective general anesthesia, ASA I or II, regardless of gender or weight, were stratified according to age: group R1 18-44 years, group R2 45-59 years, and group R3 60-80 years. The initial dose of prophylactic remifentanil before rocuronium injection was set at 1 μg/kg lean body weight (LBW). The remifentanil doses were adjusted according to the degree of injection pain using the Dixon sequential method, with a ratio of 1.1 between adjacent doses. Injection pain was graded, and the occurrence of injection pain and adverse reactions were recorded. The ED

resultsThe ED

conclusionsProphylactic intravenous remifentanil can prevent rocuronium injection pain, and its ED

trial registrationClinicalTrials.gov: NCT05217238 (registration date 18 Dec 2021).

Indexed as

AgeInjection painMedian effective doseRemifentanilRocuronium

Identifiers

PMID36884108
PMCPMC10199981
OpenAlexW4323533061

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.